Moderna Inc. (MRNA) Stock Analysis 2026

Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics. The company's mRNA COVID-19 vaccine (Spikevax) generated $36B+ in cumulative revenue and validated mRNA as a viable drug development platform. Post-pandemic, Moderna is building on this platform to develop vaccines for RSV (approved 2024), flu, cancer (personalized neoantigen vaccines with Merck), rare diseases, and autoimmune conditions. The company has the broadest mRNA pipeline in the industry with 40+ programs.

This chart shows how Moderna's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.

Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.

Every investment has two sides. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks that could cause the investment to underperform. Good investors read both sides carefully before deciding. A strong bull case with manageable bear risks typically makes for a more compelling investment.